Last updated: June 11, 2026
Kisqali Femara co-pack (copackaged) suppliers: What manufacturing, packaging, and clinical-supply vendors support Novartis’s Kisqali + letrozole bundle
Executive summary: No public, reliably verifiable source identifies named “suppliers” or third-party manufacturers for the Kisqali Femara co-pack (copackaged) product’s drug substance, finished dosage forms, packaging, or co-pack assembly. Without confirmed manufacturer/packager identities tied to specific labels, NDCs, or contracts, a defensible supplier list cannot be produced.
Who supplies the drugs inside “Kisqali Femara co-pack (copackaged)”
Answer: The co-pack contains two branded products:
- Kisqali (ribociclib)
- Femara (letrozole)
Public supplier identification typically requires one of the following to be verifiable in a source: (1) an NDC-linked label identifying “manufactured for” and facility sites, (2) an FDA SPL entry showing listed manufacturing/packaging sites, or (3) a contract manufacturing/packaging announcement tied to the specific co-pack SKU. None is provided here.
Kisqali (ribociclib) supply chain naming
Answer: Named suppliers are not provided in the input.
Femara (letrozole) supply chain naming
Answer: Named suppliers are not provided in the input.
Which contract manufacturers pack and assemble the Kisqali + Femara co-pack
Answer: No named contract manufacturer or co-pack assembly vendor is provided.
What “co-pack” usually means in pharma
A co-pack typically involves:
- producing finished dosage forms for each component separately
- kitting and bundling them under one SKU or prescription product configuration
- applying shared labeling, unit-of-use packaging, and distribution master packaging
Named vendors are normally discoverable only from labeler/manufacturer statements tied to a specific NDC/SKU.
How to identify the co-pack assembly site
A definitive supplier list requires label-level identification of:
- “Manufactured for” / “Packed by” / “Distributed by”
- packaging facility address
- labeler of record and site codes in FDA SPL
Those identifiers are not provided in the input.
What is the Orange Book status of Kisqali Femara co-pack and does it list manufacturing sites
Answer: No Orange Book entry or manufacturing site mapping is provided for the specific co-pack.
Orange Book typically lists patent and exclusivity, not co-pack suppliers
Orange Book is patent/exclusivity focused. Co-pack supplier identification usually comes from:
- FDA drug labeling and SPL manufacturing site disclosures
- NDC labeler/manufacturer fields
- inspection databases tied to site identifiers
No such details are provided here.
When does the Kisqali + Femara co-pack lose exclusivity and how does that affect suppliers
Answer: No co-pack exclusivity dates are provided.
What matters for supplier switching
Even after exclusivity or patent expiry, supplier transitions are driven by:
- manufacturing capacity and regulatory qualification
- packaging line validation and audit outcomes
- supply continuity commitments and distribution agreements
No timeline data is included.
Which companies compete for co-packing services for oncology fixed combinations
Answer: No competitive supplier set is provided.
Common co-pack/kit service categories
- blister and bottle packaging
- unit-dose dispensing and kitting
- multi-product packaging systems
- 340B and specialty distribution operations
No vendor shortlist can be stated without source-backed evidence tied to this specific co-pack.
What regulatory filings reveal the co-pack suppliers
Answer: No FDA filing identifiers (NDC, labeler code, SPL submission, supplement number) are provided.
SPL fields that identify sites
Typical SPL datasets include:
- applicant/labeler
- manufacturing site addresses for each role (manufacturer, packager, labeler)
- product type and packaging configuration
No such data is provided in the input.
Key Takeaways
- The co-pack product “Kisqali Femara co-pack (copackaged)” includes ribociclib (Kisqali) and letrozole (Femara).
- A named supplier list for the co-pack’s manufacturing, packaging, or kitting assembly cannot be produced from the provided information.
- Supplier identification in practice requires NDC/SPL/label-level facility disclosures tied to the exact co-pack SKU.
FAQs
-
How can I verify the packager for a co-pack SKU like Kisqali + Femara?
Verify “manufactured for/packed by” and site addresses on the exact NDC/SKU label or its FDA SPL entry.
-
Does FDA Orange Book list the co-pack manufacturer or kit assembly vendor?
Orange Book mainly lists patents/exclusivity; manufacturing/packaging sites come from labeling/SPL disclosures.
-
Are co-pack assembly suppliers the same as the finished drug manufacturers?
Often they differ: finished drug manufacturers produce components; a separate vendor may kit and co-package.
-
What documents identify the exact labeler of record for a co-pack?
The labeler/manufacturer fields in NDC-related label data and FDA SPL records.
-
Do supplier contracts change after exclusivity milestones?
They can, driven by capacity, regulatory qualification, and supply continuity; changes still require site-level disclosures.
References (APA)
No sources were provided or cited because no verifiable supplier list for “Kisqali Femara co-pack (copackaged)” can be derived from the input.
